Physician profile
Joe Mcdonald
NPI 1518187137
$2,600.55
in general payments reported to CMS, 2019-2025
26 companies · $650 in 2025
The $650 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.33 · 2020: $196 · 2021: $110 · 2022: $401 · 2023: $502 · 2024: $725 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,020.71 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $216.18 | 2022 | |
| Exact Sciences Corporation | $204.76 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $152.40 | 2023-2025 | Wegovy, Saxenda |
| Galderma Laboratories, L.P. | $150.00 | 2020 | |
| Pfizer INC. | $100.59 | 2024-2025 | |
| Antares Pharma, INC. | $75.10 | 2022-2024 | Xyosted |
| Sobi, INC | $72.48 | 2024 | |
| Merck Sharp & Dohme LLC | $61.81 | 2020-2024 | Gardasil, Gardasil 9, Capvaxive |
| Tolmar, INC. | $55.22 | 2023-2025 | Jatenzo |
| Axsome Therapeutics, INC. | $53.09 | 2025 | Auvelity |
| Lilly USA, LLC | $52.27 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Indivior INC. | $51.75 | 2025 | Sublocade |
| Glaxosmithkline, LLC. | $46.65 | 2021-2023 | Shingrix, Arexvy |
| Alkermes, INC. | $37.53 | 2022-2024 | Vivitrol |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $36.58 | 2021-2022 | |
| Abbott Laboratories | $35.80 | 2024-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $32.69 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $25.59 | 2021 | |
| Halozyme INC | $24.89 | 2023 | |
| Idorsia Pharmaceuticals US INC | $23.22 | 2024 | Quviviq |
| Linus Health, INC. | $19.86 | 2023 | |
| Hikma Pharmaceuticals USA | $16.50 | 2024 | Ryaltris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.42 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $11.24 | 2020 | |
| Clarus Therapeutics INC. | $10.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joe Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.